Vifor Pharmas hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

04:36 EDT 13 May 2019 | Pharmaceutical Business Review

The study has showed a significantly higher proportion of patients with resistant hypertension (RHTN) and CKD taking Veltassa remained on spironolactone therapy compared against patients taking placebo at

Vifor Pharmas hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

More From BioPortfolio on "Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study"